EXHIBIT 1

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

USDC SDNY
DOCUMENT
ELECTRONICALLY FILED
DOC #:
DATE FILED: 9/19/2017

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

Kowa Company, Ltd., et al.,

Plaintiffs,

v.

Amneal Pharmaceuticals, LLC

Defendant.

Civil Action No. 14-CV-2758 (PAC)

Kowa Company, Ltd., et al.,

Plaintiffs,

v.

Apotex, Inc., et al.,

Defendants.

Civil Action No. 14-CV-7934 (PAC)

FINDINGS OF FACT AND CONCLUSIONS OF LAW

TABLE OF CONTENTS

TABLE OF ABBREVIATIONS

INTRODUCTION AND LEGAL STANDARDS

I. The Hatch-Waxman Act and ANDA Filings 5
II. The Parties 6
III. Livalo® 7
IV. The '993 Patent 8
V. The Instant Dispute 12
VI. Legal Standards 13
a. Presumption of Patent Validity 13
b. Affirmative Defense of Patent Invalidity 13

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

i. Anticipation (35 U.S.C. § 102) 14
ii. Obviousness (35 U.S.C. § 103) 16
c. Infringement 18
i. Claim Construction 19
VII. Crystals and Polymorphs 20
VIII. X-Ray Powder Diffraction and Characterization 23
IX. Jurisdiction 28
X. Person of Ordinary Skill in the Art 28
XI. Validity of the '993 Patent 29
a. Anticipation (35 U.S.C. § 102) 29
i. EP '406 31
ii. The '993 Patent Prosecution History 31
iii. Defendants' Inherency Arguments 37
iv. Conclusion Regarding Inherent Anticipation 40
b. Obviousness (35 U.S.C. § 103) 48
i. Level of Ordinary Skill in the Art 50
ii. Scope and Content of the Prior Art and Differences Between Claimed Subject Matter and the Prior Art 50
iii. Whether Obtaining Form A Would Have Been Obvious to a POSA in 2003 52
iv. Objective Indicia of Nonobviousness (Secondary Considerations) 59
v. Conclusion Regarding Obviousness 75
c. Conclusion Regarding Validity 75
XII. Infringement of the '993 Patent 76
a. Step One: Construing the Asserted Claims 77
i. Claims 1 and 24: "exhibits a characteristic x-ray diffraction pattern with characteristic peaks expressed in 2θ at . . ." 77
ii. Claims 23 and 25: "having an x-ray powder diffraction pattern substantially as depicted in Fig. 1 . . ." 80
b. Step Two: Comparison of Asserted Claims to Apotex's Proposed ANDA Product 81
i. Apotex's Proposed ANDA Product 82
ii. Dr. Kaduk's Analysis and Conclusions 85
iii. Dr. Sacchetti's Analysis and Conclusions 89

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

iv. Claims 1 and 24 91
v. Claims 23 and 25 94
vi. Claim 22 95
c. Conclusion Regarding Infringement 96
CONCLUSION

TABLE OF ABBREVIATIONS

'993 Patent	U.S. Patent No. 8,557,993
ANDA	Abbreviated New Drug Application
API	Active pharmaceutical ingredient
DMF	Drug master file
EPO	European Patent Office
EP '406	European Patent Application No. EP 0 520 406A1
FDA	U.S. Food and Drug Administration
IDS	Information Disclosure Statement
KCL	Kowa Company, Ltd.
KPA	Kowa Pharmaceuticals America, Inc.
MSN	MSN Laboratories Pvt. Ltd.
NCI	Nissan Chemical Industries, Ltd.
PTO	U.S. Patent and Trademark Office
TPO	Third Party Observation
USP	U.S. Pharmacopeia
XRPD or PXRD	X-ray powder diffraction

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

HONORABLE PAUL A. CROTTY, United States District Judge:

This is a Hatch-Waxman patent infringement litigation initiated by Plaintiffs Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries, Ltd. (collectively, "Plaintiffs"), manufacturers of the cholesterol-lowering drug Livalo®, against defendants Amneal Pharmaceuticals, LLC ("Amneal"), and Apotex, Inc. and Apotex Corp. ("Apotex"), generic drug manufacturers (together, "Defendants").[1] Plaintiffs allege that Defendants' proposed Abbreviated New Drug Application ("ANDA") products would infringe U.S. Patent No. 8,557,993 (the "'993 patent"). Both Amneal and Apotex contend that the '993 patent is invalid as (1) anticipated based on prior art, under 35 U.S.C. § 102(b); and/or (2) obvious in view of prior art, under 35 U.S.C. § 103. Only Apotex asserts non-infringement; Amneal concedes infringement.

The Court held a ten-day bench trial from January 17 through January 30, 2017, with closing arguments on February 3, 2017. Each of the parties submitted extensive post-trial briefing on the '993 patent's validity and infringement. After considering the documentary evidence and testimony, the Court makes the following findings of fact and conclusions of law pursuant to Fed. R. Civ. P. 52(a). As set forth below, the Court determines that the '993 patent is valid; and that Apotex's proposed ANDA product would infringe the '993 patent.

[1] Plaintiffs commenced this litigation against eight generic drug manufacturer defendants. Defendants asserted defenses of invalidity and non-infringement. Four defendants settled before commencement of the ten-day bench trial. The fifth defendant settled mid-trial; and the sixth settled post-trial. Only Amneal and Apotex remain. On April 11, 2017, the Court issued its Findings of Fact and Conclusions of Law regarding the other patent at issue at trial, U.S. Patent No. 5,856,336, finding it valid. (*Kowa Co., Ltd. v. Amneal Pharm., LLC*, No. 14-CV-2758 (PAC) (S.D.N.Y. Apr. 11, 2017)).

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.